Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target

Avidity Biosciences +0.57%

Avidity Biosciences

RNA

47.51

+0.57%

Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ: RNA) with a Buy and maintains $60 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via